Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 256

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 256
---
 proteostasis modulators. The company currently has four programs under pipeline in clinical stage, including its lead asset, AST301, a pDNA based cancer vaccine for breast cancer. The company also developed a machine -learningbased immuno -informaticsplatform, Th -VAC, for its drug development, and entered in -licensingagreement a Seattle based biotech company. The company was introduced to BLAC on March 6, 2023 by a Seoul, Korea based biotech company. Mr. Hwang of BLAC was also introduced to the company by Steven Reed of HDT Bio Corp., and a Director of BLAC. “ Company L ”, a clinical stage company, with clinically proven stem cell expansion technology that also serves as starting material for generation of multiple immune effector cells. The company was the first group to develop clinical universal non -HLAmatched allogeneic and off -the -shelfcell therapies with excellent safety profiles and owns a diverse pipeline of multiple effector cells allows combination approaches to enhance efficacy and overcome the limitation of current treatment with CAR -Tmonotherapy. The company also developed a cell therapy for first line AML (Phase 2/3 ready program) with preliminary efficacy and safety data from global RCT phase 2. The company was introduced to BLAC on March 9, 2023 by a Seattle, Washington based venture capital firm. BLAC and OSR Holdings Discussions regarding Business Combination Initial Discussions Beginning several years ago, OSR Holdings has had and continues to have a standing policy of holding a firm -widemeeting every Monday morning at 10:00 AM Seoul Time to discuss all matters relating to OSR Holdings’ business. Attendees include (now former) Managing Director Sung Hoon Chung, (now former) Managing Director and Chief Operating Officer Sung Jae Yu, (now former) Chief Financial Officer Soo Eun Nam, Technology Analyst Dr. Yeiseok Kim, Analyst Taemin Lee, as well as Chairman and (now former) Chief Executive Officer Kuk Hyoun Hwang. As noted previously, Mr. Hwang also serves as a director and Chief Executive Officer of BLAC. Immediately following BLAC’s IPO on February 14, 2023, and as set forth fully below, BLAC began to consider companies with which to conduct a business combination. This included the possible option of a business combination with its affiliated company OSR Holdings. Thus, beginning the following week, on Monday, February 20, 2023, BLAC began